

### Remarks/Arguments

The amendments to claim 1 are supported as follows:


1. The addition of “C<sub>1-6</sub> alkyl ester” is supported by p. 15, line 1, of the specification.
2. The addition of “thienyl, furyl, pyridinyl, benzothienyl, or benzofuryl” is supported by claim 7.
3. The addition of “are independently selected from: a hydrocarbon moiety having from 1 to 4 carbon atoms, CO<sub>2</sub>H, alkoxy having from 1 to 3 carbon atoms, CN, NO<sub>2</sub>, CF<sub>3</sub>, F, Cl, Br, I, and SO<sub>3</sub>H” is supported by p. 9, lines 17-25 of the specification.

### ***Claim Rejections – 35 U.S.C. § 112***

The claims were rejected as being indefinite. The grounds of rejection are addressed in the order presented by the Office.

- i) The term “comprising” has been replaced by “having a formula.” Applicants believe that this should overcome the rejection.
- ii) The phrase “C<sub>1-6</sub> alkyl ester” has been inserted before “prodrug.” Applicants believe this is sufficiently definite to overcome the rejection.

The Office alleges that using CH<sub>2</sub>CHOH is indefinite because the group allegedly “has to be divalent.” Applicants respectfully point out that in the structure:



, J is CH<sub>2</sub>CHOH without violating any rules of chemistry. Therefore, Applicants believe that the term is not indefinite.

iii) The substituents “a hydrocarbon moiety having from 1 to 4 carbon atoms, CO<sub>2</sub>H, alkoxy having from 1 to 3 carbon atoms, CN, NO<sub>2</sub>, CF<sub>3</sub>, F, Cl, Br, I, and SO<sub>3</sub>H” have been designated for E. Therefore, this rejection is believed to be overcome.

iv) The term “heteroaromatic moiety” has been replaced with “thienyl, furyl, pyridinyl, benzothienyl, or benzofuryl.” Therefore, this rejection is believed to be overcome.

v) Applicants have added “a pharmaceutically acceptable excipient” to the claim as suggested by the Office. Therefore, this rejection is believed to be overcome.

vi) Applicants have amended the preamble of claim 13 to read “A method of treating glaucoma or ocular hypertension.” Therefore, this rejection is believed to be overcome.

In view of the arguments and the amendments made herein, Applicants respectfully request that a timely Notice of Allowance be issued in this case.

Please charge Deposit Account 01-0885 for any fees related to this response.

Date: September 25, 2007

Respectfully submitted,

/Brent A. Johnson/  
Brent A. Johnson  
Registration No. 51,851  
Agent of Record

Please send all inquiries and correspondence to:

Brent A. Johnson  
Allergan, Inc. (T2-7H)  
2525 Dupont Drive  
Irvine, CA 92612

Telephone: 714/246-4348/Facsimile: 714/246-4249